Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2017-10-16 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Bioblast Pharma Ltd., submitted to the SEC. It reports a compliance update regarding NASDAQ listing rules, specifically about regaining compliance with the minimum bid price requirement after a reverse stock split. The document is short (2563 characters) and primarily provides an update on a regulatory compliance matter rather than detailed financial data or a full report. It does not contain financial statements or detailed analysis typical of annual or interim reports. It is not an earnings release, audit report, or management discussion. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about compliance status and does not fit other more specific categories.
2017-10-16 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Bioblast Pharma Ltd. It announces a press release about the effectiveness of a five to one reverse stock split and related amendment to the company's articles of association. The document is short (2352 characters) and primarily serves as an announcement of this corporate action rather than a detailed financial report or full filing. It does not contain financial statements or detailed analysis, nor is it a transcript, audit report, or management discussion. The nature of the content fits best with a Capital/Financing Update (CAP) because it relates to a change in the company's capital structure (reverse stock split).
2017-09-25 English
6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It reports the results of an Extraordinary General Meeting (EGM) held on September 18, 2017, where shareholders approved a reverse stock split. The document is short (2470 characters) and primarily announces the voting results of the EGM. There is no detailed financial data or comprehensive report content. According to the rules, announcements of voting results at general meetings should be classified as Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-09-18 English
FORM 6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, BioBlast Pharma Ltd., with the SEC. It contains a Notice of Meeting, Proxy Statement, and Proxy Card for an Extraordinary General Meeting of Shareholders. The document is relatively short (2678 characters) and primarily announces the meeting materials rather than containing the materials themselves or detailed financial data. It references the proxy materials as attached exhibits and incorporated by reference, indicating this filing is an announcement of these materials rather than the materials themselves. Therefore, this filing fits best under Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2017-08-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It includes a press release announcing financial results for the quarter ended June 30, 2017. The document is relatively short (2384 characters) and primarily serves as an announcement of the financial results rather than containing the full financial statements or detailed analysis itself. The text states that the press release is attached as Exhibit 99.1 and that the GAAP financial statements are incorporated by reference into other registration statements. This indicates the document is an announcement of financial results rather than the full interim or quarterly report. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a Form 6-K filing with a press release and references to other filings, without substantive financial data or detailed financial statements within this document itself.
2017-08-04 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release about engaging a business development partner, JSB-Partners, and includes no financial statements or detailed financial data. The document is short (2333 characters) and primarily serves as an announcement rather than a full report. It does not contain quarterly or annual financial results, audit information, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.